Novel BTK inhibitors may be helpful in reducing MM tumor burden partly and indirectly through reduction of osteolytic activity in bone microenvironment, and directly when combined with clinical cell proliferation inhibitors such as certain alkylating agents and proteasome inhibitors. Here, BTK is linked to Miyoshi myopathy.